{"id":"tp-53340","type":"article-newspaper","title":"Merck Says Efinopegdutide Meets Phase 2b MASH Trial Goal","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53340","datePublished":"2026-11-10T21:40:17.000Z","dateModified":"2026-11-10T21:40:17.000Z","language":"en","abstract":"The MK-6024-013 trial evaluated once-weekly subcutaneous efinopegdutide at 4 mg, 7 mg and 10 mg in adults with MASH and stage F2 or F3 liver fibrosis.","section":"Business","references":[]}